General
Preferred name
LENVATINIB
Synonyms
E7080, ER-203492-00, Lenvatinib Mesylate ()
E7080 (mesylate) ()
E7080 ()
E7080 (Lenvatinib) ()
LENVATINIB MESYLATE ()
Lenvatinib (mesylate) ()
E7080 mesylate ()
Lenvatinib (E7080) ()
Lenvatinib (E7080) Mesylate ()
LenvatinibA-13861E-70806-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]-amino]phenoxy]-7-methoxy- ()
E-7080 ()
ER-203492-00 ()
KISPLYX ()
LENVIMA ()
E-7080 MESYLATE ()
Lenvatinib mesilate ()
Lenvatinib methanesulfonate ()
Lenvatinib ()
Lenvatinib-d4 ()
P&D ID
PD003669
CAS
417716-92-8
857890-39-2
2264050-65-7
Tags
available
drug
Approved by
EMA
PMDA
FDA
First approval
2015
Drug indication
Ovarian cancer
Hepatocellular carcinoma
Neoplasm
Solid tumour/cancer
Non-small-cell lung cancer
Melanoma
Thyroid cancer
Renal cell carcinoma
Metastatic melanoma
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION Lenvatinib is indicated for the treatment of following conditions.; ; - Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.; ; - Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus following one prior antiangiogenic therapy.; ; - First-line treatment of unresectable hepatocellular carcinoma (HCC).
DESCRIPTION Lenvatinib is a potent inhibitor of VEGFR-2 (KDR) and VEGFR-3 (FLT4) . (GtoPdb)
DESCRIPTION Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].
PRICE 51
DESCRIPTION Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].
PRICE 34
DESCRIPTION inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta (Informer Set)
DESCRIPTION Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. (PKIDB)
DESCRIPTION Lenvatinib is a receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma. (Enamine Bioactive Compounds)
DESCRIPTION Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity. (TargetMol Bioactive Compound Library)
DESCRIPTION Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities. (TargetMol Bioactive Compound Library)
Cell lines
11
Organisms
0
Compound Sets
27
AdooQ Bioactive Compound Library
A10340
Axon Medchem Screening Library
3165
Cayman Chemical Bioactives
19375
29832
28615
ChEMBL Approved Drugs
CHEMBL1289601
CHEMBL2105704
ChEMBL Drugs
CHEMBL1289601
CHEMBL2105704
Clinical kinase drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB09078
DrugBank Approved Drugs
DB09078
DrugCentral
4942
DrugCentral Approved Drugs
4942
DrugMAP
DMB1IU4
DrugMAP Approved Drugs
DMB1IU4
Enamine Bioactive Compounds
EBC-11343
EU-OPENSCREEN Bioactive Compound Library
EOS101608
Guide to Pharmacology
7426
Informer Set
628639
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1289601
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL1289601
MedChem Express Bioactive Compound Library
HY-10981
HY-10981A
NCATS Inxight Approved Drugs
EE083865G2
NIH Approved Oncology Drugs
440803283
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
E7080
lenvatinib-mesylate
TargetMol Bioactive Compound Library
T0520
T8541
External IDs
62
Properties
(calculated by RDKit )
Molecular Weight
426.11
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
4.07
TPSA
115.57
Fraction CSP3
0.19
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
FLT1
FLT3
KDR
KIT
PDGFRA
PDGFRB
c-Kit
FGFR
FGFR1
PDGFR
PDGFRα
PDGFRβ
RET
VEGFR
VEGFR1
VEGFR3
VEGFR1/FLT1
VEGFR2/KDR
VEGFR3/FLT4
FLT4, KDR
RTK inhibitor
c-Kit,c-RET,FGFR,PDGFR,VEGFR
FLT4
FGFR2
FGFR3
FGFR4
Compound status
FDA
Targets
KDR,FLT4
MOA
FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor
Indication
thyroid cancer
Pathway
Angiogenesis
Apoptosis
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Source data